<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Alemtuzumab is effective therapy for B- and T-cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> (LPD) but is associated with prolonged <z:hpo ids='HP_0001888'>lymphopenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Myeloid haematological toxicities are less well described, especially in T-cell disorders, and are usually transient </plain></SENT>
<SENT sid="2" pm="."><plain>We report myeloid toxicities in a phase II trial of alemtuzumab for T-cell LPD </plain></SENT>
<SENT sid="3" pm="."><plain>Five of 11 patients treated developed severe <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Three cases had prolonged cytopenias (32-88+ weeks), including two with severe marrow <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> </plain></SENT>
<SENT sid="5" pm="."><plain>We observed three incidences of trilineage morphological <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, two with new clonal cytogenetic abnormalities </plain></SENT>
<SENT sid="6" pm="."><plain>Alemtuzumab can be associated with prolonged severe multilineage cytopenias, marrow <z:mpath ids='MPATH_133'>hypoplasia</z:mpath> and <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> in T-cell LPD </plain></SENT>
</text></document>